Clinical Trial Update: Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment [Phase 2]

View source ↗

Summary

Phase 2 study evaluating re-challenge with gefitinib (Iressa) in advanced EGFR-mutant non-small cell lung cancer patients who previously responded to gefitinib,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-23